
Beijing Northland Biotechnology’s gene therapy drug NL003 gets approval for market
On May 28, the NMPA website shows that Beijing Northland Biotechnology’s Class 1 new drug **NL003** is approved for market in China for the treatment of ulcers caused by critical limb ischemia (CLI). NL003 injection is a novel plasmid-based gene…









